Nefopam Hydrochloride Glenmark Pharmaceuticals Europe

Nefopam Hydrochloride, the active ingredient in Nefopam Hydrochloride Glenmark Pharmaceuticals Europe, is a non‑opioid analgesic presented as an oral formulation for systemic use. It is indicated for the management of moderate pain and post‑operative pain in adult patients.

GNH USA supplies Nefopam Hydrochloride Glenmark Pharmaceuticals Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation to support import and distribution. Customers benefit from reliable logistics and technical support throughout the supply chain.

Nefopam Hydrochloride is used to alleviate pain conditions that involve central sensitization. - Moderate pain: provides analgesia for acute or chronic moderate‑intensity pain. - Post‑operative pain: reduces pain following surgical procedures. - Musculoskeletal pain: helps manage pain associated with strains, sprains, and back discomfort. - Dental pain: offers relief after dental extractions or procedures.

Nefopam may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dry mouth: reduced salivation leading to throat discomfort. - Sweating: increased perspiration, especially in warm environments. - Dizziness: transient light‑headedness or imbalance. - Blurred vision: temporary visual disturbances. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Seizures: risk of convulsive episodes, particularly at high doses. - Severe hypotension: sudden drop in blood pressure requiring medical attention. - Allergic reactions: rash, pruritus, or anaphylaxis. - Tachycardia: rapid heart rate that may be symptomatic. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Blood dyscrasias: rare cases of agranulocytosis or thrombocytopenia.

Before prescribing Nefopam, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Assess renal and hepatic function: adjust use if organ impairment is present. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Monitor cardiovascular status: watch for hypotension or tachycardia. - Use caution in seizure disorders: risk of convulsions may be increased. - Do not discontinue abruptly: taper if long‑term therapy is stopped. - Store at room temperature: keep in the original pack, protect from moisture and light.

Nefopam can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: may precipitate hypertensive crisis. - SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin syndrome. - Anticholinergic drugs: additive anticholinergic burden.

Moderate Interactions (Monitor Closely): - CNS depressants: may enhance sedation or dizziness. - Beta‑blockers: possible alteration of heart‑rate response. - Diuretics: may potentiate hypotensive effects.